cyc 202 has been researched along with gsk 1070916 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (gsk 1070916) | Trials (gsk 1070916) | Recent Studies (post-2010) (gsk 1070916) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 23 | 0 | 19 |
| Protein | Taxonomy | cyc 202 (IC50) | gsk 1070916 (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 1.1795 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.076 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.077 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.076 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.042 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.074 | |
| Serine/threonine-protein kinase SIK1 | Homo sapiens (human) | 0.07 | |
| Angiopoietin-1 receptor | Homo sapiens (human) | 0.059 | |
| Aurora kinase B | Homo sapiens (human) | 0.0081 | |
| Inner centromere protein | Homo sapiens (human) | 0.0032 | |
| Targeting protein for Xklp2 | Homo sapiens (human) | 1.1 | |
| Aurora kinase C | Homo sapiens (human) | 0.0065 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
1 other study(ies) available for cyc 202 and gsk 1070916
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |